Long term treatment of HIV-infection with TMC278

Number of patents in Portfolio can not be more than 2000

United States of America

PATENT NO RE50189
SERIAL NO

17473424

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

This invention relates to the use of a parenteral formulation comprising an anti-virally effective amount of TMC278 or a pharmaceutically acceptable acid-addition salt thereof, and a carrier, for the manufacture of a medicament for the treatment of a subject being infected with HIV, wherein the formulation is to be administered intermittently at a time interval of at least one week.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • JANSSEN SCIENCES IRELAND UNLIMITED COMPANY

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Baert, Lieven Elvire Colette Bruges, BE 34 91
Kraus, Guenter Sint-Katelijne-Waver, BE 11 7
Van, 'T Klooster Gerben Albert Eleutherius Breda, NL 8 7

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
3.5 Year Payment $1600.00 $800.00 $400.00 Apr 29, 2028
7.5 Year Payment $3600.00 $1800.00 $900.00 Apr 29, 2032
11.5 Year Payment $7400.00 $3700.00 $1850.00 Apr 29, 2036
Fee Large entity fee small entity fee micro entity fee
Surcharge - 3.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00